Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18204
Country/Region: Kenya
Year: 2016
Main Partner: University of Nairobi
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $3,285,296 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $887,636
Care: TB/HIV (HVTB) $185,016
Care: Pediatric Care and Support (PDCS) $159,726
Testing: HIV Testing and Counseling (HVCT) $266,081
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $489,153
Treatment: Adult Treatment (HTXS) $933,094
Treatment: Pediatric Treatment (PDTX) $364,590
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: <1 2017 878
HTS_TST Age/sex: 1-9 2017 16,276
HTS_TST Age/sex: 10-14 Female 2017 7,518
HTS_TST Age/sex: 10-14 Male 2017 7,123
HTS_TST Age/sex: 15-19 Female 2017 11,373
HTS_TST Age/sex: 15-19 Male 2017 10,941
HTS_TST Age/sex: 20-24 Female 2017 34,030
HTS_TST Age/sex: 20-24 Male 2017 27,871
HTS_TST Age/sex: 25-49 Female 2017 63,087
HTS_TST Age/sex: 25-49 Male 2017 61,540
HTS_TST Age/sex: 50+ Female 2017 11,191
HTS_TST Age/sex: 50+ Male 2017 10,816
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 20,110
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 17,685
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 155,148
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 132,679
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 325,624
HTS_TST Service Delivery Point (Facility): Index testing 2017 3,789
HTS_TST Service Delivery Point (Facility): Inpatient 2017 15,640
HTS_TST Service Delivery Point (Facility): Other PITC 2017 2,079
HTS_TST Service Delivery Point (Facility): Outpatient 2017 207,071
HTS_TST Service Delivery Point (Facility): Pediatric 2017 2,706
HTS_TST Service Delivery Point (Facility): PMTCT 2017 15,645
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 576
HTS_TST Service Delivery Point (Facility): VCT 2017 78,733
HTS_TST Sum of Age/Sex disaggregates 2017 245,490
HTS_TST Sum of Aggregated Age/Sex <15 2017 37,795
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 287,827
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 325,622
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 207
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 196
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 2,017
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 1,908
PMTCT_ART Already on ART at beginning of current pregnancy 2017 769
PMTCT_ART New on ART 2017 288
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 64,605
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 726
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 288
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 19
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 23
PMTCT_EID Sum of Infant Age disaggregates 2017 1,014
PMTCT_STAT By Age (DREAMS SNUs ONLY): <15 2017 17
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 86
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 553
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 1,181
PMTCT_STAT By: Known positives at entry 2017 1,663
PMTCT_STAT By: Number of new positives identified 2017 592
PMTCT_STAT Number of new ANC and L&D clients 2017 64,605
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 64,605
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 3
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 16
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 50+ 2017 3
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 1
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 6
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 50+ 2017 1
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,255
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 17
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 86
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 553
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 1,181
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 426
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 520
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 954
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 954
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 8,036
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 8,012
TB_SCREENDX Screen Result: Screened Positive for TB 2017 8,923
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 24,914
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 13,914
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 3,168
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 2,508
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 44,604
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 134
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,155
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 171
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,558
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 5,018
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 5,018
TX_CURR Age/Sex: <1 2017 815
TX_CURR Age/Sex: <1-9 2017 3,447
TX_CURR Age/Sex: 10-14 Female 2017 691
TX_CURR Age/Sex: 10-14 Male 2017 723
TX_CURR Age/Sex: 15-19 Female 2017 456
TX_CURR Age/Sex: 15-19 Male 2017 2,251
TX_CURR Age/Sex: 20-24 Female 2017 2,212
TX_CURR Age/Sex: 20-24 Male 2017 584
TX_CURR Age/Sex: 25-49 Female 2017 18,661
TX_CURR Age/Sex: 25-49 Male 2017 8,297
TX_CURR Age/Sex: 50+ Female 2017 3,685
TX_CURR Age/Sex: 50+ Male 2017 2,800
TX_CURR Aggregated Age/Sex: <15 Female 2017 3,168
TX_CURR Aggregated Age/Sex: <15 Male 2017 2,508
TX_CURR Aggregated Age/Sex: 15+ Female 2017 24,808
TX_CURR Aggregated Age/Sex: 15+ Male 2017 13,914
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 44,604
TX_CURR Sum of age/sex disaggregates 2017 2,707
TX_CURR Sum of Aggregated Age/Sex <15 2017 5,676
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 38,722
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 44,398
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 232
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 186
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 4,235
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 1,922
TX_NEW By Age/Sex: <1 2017 30
TX_NEW By Age/Sex: 1-9 2017 206
TX_NEW By Age/Sex: 10-14 Female 2017 96
TX_NEW By Age/Sex: 10-14 Male 2017 84
TX_NEW By Age/Sex: 15-19 Female 2017 185
TX_NEW By Age/Sex: 15-19 Male 2017 22
TX_NEW By Age/Sex: 20-24 Female 2017 376
TX_NEW By Age/Sex: 20-24 Male 2017 323
TX_NEW By Age/Sex: 25-49 Female 2017 3,034
TX_NEW By Age/Sex: 25-49 Male 2017 1,208
TX_NEW By Age/Sex: 50+ Female 2017 620
TX_NEW By Age/Sex: 50+ Male 2017 359
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 6,543
TX_NEW Sum of Age/Sex disaggregates 2017 6,307
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 6,575
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 35,702
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 40,226
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 2,882
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 2,280
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 22,528
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 12,536
TX_PVLS Numerator: Indication: Routine 2017 40,226
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 2,857
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 2,620
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 22,019
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 12,445
TX_PVLS_den Denominator: Indication: Routine 2017 29,546
TX_PVLS_den Denominator: Indication: Targeted 2017 164
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 29
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 194
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 92
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 83
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 172
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 22
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 346
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 294
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,692
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,096
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 565
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 330
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 218
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 176
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,692
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,742
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 5,897
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 6,543
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 30
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 206
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 96
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 84
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 185
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 22
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 376
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 323
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,034
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,208
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 620
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 359
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 230
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 186
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4,215
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,912
Cross Cutting Budget Categories and Known Amounts Total: $399,980
Gender: Gender Based Violence (GBV) $199,990
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $199,990
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research